Internal Medicine Doctors in Juneau, AK Accepting Medicare

7 Internal Medicine doctors found. Showing 1 - 7

Catherine Louise Peimann, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 641 W Willoughby Ave, #201, Juneau, AK 99801 Phone: 907-586-8100    Fax: 907-586-8102

Dr. William Cole, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 10301 Glacier Hwy, Juneau, AK 99801 Phone: 907-789-2910    Fax: 907-789-5545

Dr. Alex Malter, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10301 Glacier Hwy, Juneau, AK 99801 Phone: 907-789-2910    Fax: 907-789-5545

Dr. Melissa Ann Hynes, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 10301 Glacier Hwy, Juneau, AK 99801 Phone: 907-789-2910    Fax: 907-789-5545

Dr. Nathaniel L Haddock, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10301 Glacier Hwy, Juneau, AK 99801 Phone: 907-789-2910    Fax: 907-789-5545

Paul L Weiden, MD Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8631    Fax: 907-796-8455

Anne Bakker Standerwick, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 641 W Willoughby Ave, #201, Juneau, AK 99801 Phone: 907-586-8100    Fax: 907-586-8102

News Archive

Scientists find efficient and easy way to mass produce GABAergic neurons for laboratory use

Scientists from Singapore have streamlined the process of using human stem cells to mass produce GABAergic neurons (GNs) in the laboratory.

Supporters of Medicaid expansion fight to be heard in some statehouses

Mississippi House Democrats blocked passage of the state's Medicaid budget Sunday to force a vote on expanding the program, while supporters and critics do battle in Missouri, Montana and Arkansas.

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

NIH announces new program to study patients with mystery diseases

NIH on Monday announced a pilot program that will study extremely rare diseases in people and could provide some no-cost care for study participants, the AP/San Francisco Chronicle reports.

Read more Medical News

› Verified 8 days ago